Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer of Unknown Primary Origin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Cancer of Unknown Primary Origin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-005865-67 Sponsor Protocol Number: PXD101-CLN17 Start Date*: 2008-12-11
    Sponsor Name:Topotarget A/S
    Full Title: An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated c...
    Medical condition: Patients with previously untreated carcinoma of unknown primary
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004562-33 Sponsor Protocol Number: CheCUP Start Date*: 2019-12-04
    Sponsor Name:University Heidelberg, Med. Fac. repr. by University Hospital and its Commercial Managing Director
    Full Title: A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or ...
    Medical condition: Cancer of unknown primary site (CUP-Syndrome), relapsed/refractory to platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007460 Carcinoma of unknown primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004163-12 Sponsor Protocol Number: RP2017-001 Start Date*: 2018-01-28
    Sponsor Name:ReposPharma
    Full Title: A phase 2a TDM-guided clinical study on the safety and efficacy of mebendazole in patients with advanced gastrointestinal cancer or cancer of unknown origin
    Medical condition: Squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10017985 Gastrointestinal neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001912-38 Sponsor Protocol Number: ACR-CMOD / 2005-2 Start Date*: 2006-01-11
    Sponsor Name:ACROSS
    Full Title: PHASE II TRIAL OF THE COMBINATION OF GEMCITABINE AND OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE Estudio fase II de la combinación de gemcitabina...
    Medical condition: METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005018-47 Sponsor Protocol Number: 008-IRCC-10IIS-14 Start Date*: 2015-04-08
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: A PHASE II, RANDOMIZED, MULTICENTER STUDY TO ASSESS THE EFFICACY OF NAB-PACLITAXEL-BASED DOUBLET AS FIRST LINE THERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP): the AGNOSTOS trial
    Medical condition: Cancers of Unknown Primary (CUP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073059 Malignant neoplasm of unknown primary site PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001546-18 Sponsor Protocol Number: GETNE-T1913 Start Date*: 2019-08-19
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
    Full Title: A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment, in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (N...
    Medical condition: Unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005481-18 Sponsor Protocol Number: BNT142-01 Start Date*: 2022-04-28
    Sponsor Name:BioNTech SE
    Full Title: First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced sol...
    Medical condition: Claudin 6 (CLDN6)-positive advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043302 Testicular cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004323-20 Sponsor Protocol Number: BNT211-01 Start Date*: 2020-06-30
    Sponsor Name:BioNTech Cell & Gene Therapies GmbH
    Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-...
    Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043302 Testicular cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046766 Uterine cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007460 Carcinoma of unknown primary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001327-39 Sponsor Protocol Number: C/37/2017 Start Date*: 2018-11-05
    Sponsor Name:Imperial College London
    Full Title: A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of unknown primary - CUPem
    Medical condition: CUP, Cancer of Unknown Primary
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002858-20 Sponsor Protocol Number: ESR-15-11561-61/DUNE Start Date*: 2017-03-02
    Sponsor Name:GETNE (Grupo Español de Tumores Neuroendocrinos)
    Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial).
    Medical condition: Advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-002767-17 Sponsor Protocol Number: D0816C00020 Start Date*: 2017-12-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Pa...
    Medical condition: Non Germline BRCA Mutated Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) SI (Completed) BG (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) AT (Completed) SE (Completed) PT (Completed) NO (Completed) DK (Completed) FI (Completed) PL (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-004333-34 Sponsor Protocol Number: EORTC 55041 Start Date*: 2005-09-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I an...
    Medical condition: Histologically confirmed high-risk FIGO stage I (grade 3, or aneuploid grade 1 or 2, or clear cell), or Stages II-IV ovarian epithelial, primary peritoneal, and fallopian tube cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10033283 HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-005197-35 Sponsor Protocol Number: S1404 Start Date*: 2017-06-06
    Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    Full Title: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.
    Medical condition: High risk resected melanoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000549-15 Sponsor Protocol Number: S63678 Start Date*: 2020-08-05
    Sponsor Name:University Hospitals Leuven
    Full Title: Al18F-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors
    Medical condition: Neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003602-16 Sponsor Protocol Number: PM1183-A-014-15 Start Date*: 2022-08-18
    Sponsor Name:PHARMA MAR, S.A. SOCIEDAD UNIPERSONAL
    Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors.
    Medical condition: Selected Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005539-22 Sponsor Protocol Number: GO28076 Start Date*: 2012-10-08
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLA...
    Medical condition: Head and neck cancer of squamous cell origin
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071537 Head and neck cancer stage III PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed) HU (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-004161-68 Sponsor Protocol Number: AG013-ODOM-201 Start Date*: 2018-10-31
    Sponsor Name:Oragenics, Inc.
    Full Title: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cance...
    Medical condition: Oral mucositis (OM) induced by chemoradiation therapy (CRT) used for the treatment of head and neck cancers (HNC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001925-15 Sponsor Protocol Number: ISS20159321 Start Date*: 2018-10-22
    Sponsor Name:Alcedis GmbH
    Full Title: Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant me...
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004944-37 Sponsor Protocol Number: MK-3475-054-07 Start Date*: 2015-09-22
    Sponsor Name:Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc
    Full Title: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial o...
    Medical condition: Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) PT (Ongoing) ES (Ongoing) DK (Ongoing) AT (Ongoing) BE (Ongoing) NL (Ongoing) PL (Ongoing) FI (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001974-10 Sponsor Protocol Number: CA184-029 Start Date*: 2009-03-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORT...
    Medical condition: High Risk Stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) SE (Completed) FI (Completed) CZ (Completed) DK (Completed) DE (Completed) ES (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA